Celgene (NASDAQ:CELG)

biotech

Short Sellers Back Off Major Biotechs

The short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

Celgene Earnings Beat and Updated Guidance

Celgene Corp. (NASDAQ: CELG) released its second-quarter earnings report Thursday before the markets opened. The major biotech had $1.23 in earnings per share (EPS) on $2.28 billion in revenue, versus ...
Read Full Story »
biotech

Top Health Care Earnings for the Week Ahead

Earnings season is hitting its stride next week, and we have taken a look at companies in a variety of sectors that will be posting results next week. The health ...
Read Full Story »
biotech

Is Celgene Transforming Itself With Mergers and Pacts?

The red-hot health care sector has excited the merger and acquisition (M&A) market so far in 2015. Companies are consolidating their efforts and pipelines to pull in even more revenue. ...
Read Full Story »
Biotechnology word cloud

Short Sellers Back Off Big Biotech

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

What Celgene Now Means for Juno

As the health care sector remains hot, it is logical to expect ongoing mergers and acquisitions action to continue. Then there are the collaborative efforts within the sector that should continue. ...
Read Full Story »
DNA

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
462542665

How Much Can Celgene’s Buyback Impact Its Growth?

Celgene Corp. (NASDAQ: CELG) has seen huge growth since 2012. Its board of directors wants to keep this growth going with its most recent move. The company announced that the ...
Read Full Story »
Biotechnology word cloud

Short Sellers Lose Some Conviction Against Big Biotech

The short interest data are out for the May 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
GettyImages_183162370

Large Companies With Fastest Revenue and Earnings Growth in 2015

This year is nearing the halfway mark and analysts are beginning to project their biggest winners and losers on the year. S&P Capital IQ recently released a report regarding the ...
Read Full Story »
biotech

The Most Loved Biotechs of Big Hedge Funds

With such a mixed performance over the past decade, some of us wonder why hedge funds are so revered. Ditto for many of the so-called guru fund managers. Still, investors ...
Read Full Story »
biotech

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Combine the upcoming typical summer weakness with howls of a biotech bubble, and the recipe is in place for trouble, even for the top stocks in the industry. In a ...
Read Full Story »
dollar

Is Celgene Stumped on Its Portfolio?

Celgene Corp. (NASDAQ: CELG) released its first-quarter results before the markets opened Thursday. The biotech giant had $1.07 in earnings per share (EPS) on $2.08 billion in revenue. That compared ...
Read Full Story »
biotech

What to Expect From Celgene Earnings

Celgene Corp. (NASDAQ: CELG) is scheduled to release its first-quarter financial results before the markets open Thursday. Thomson Reuters has consensus estimates of $1.06 in earnings per share (EPS) on ...
Read Full Story »